Real-world corticosteroid use in severe pneumonia: a propensity-score-matched study
Background: Community-acquired pneumonia (CAP) is a leading cause of morbidity and mortality worldwide despite correct antibiotic use. Corticosteroids have long been evaluated as a treatment option, but heterogeneous efects on survival have precluded their widespread implementation. We aimed to eval...
| Autores: | , , , , , , , , , , , , , |
|---|---|
| Tipo de recurso: | artículo |
| Estado: | Versión publicada |
| Fecha de publicación: | 2021 |
| País: | España |
| Repositorio: | Dipòsit Digital de la UB |
| OAI Identifier: | oai:diposit.ub.edu:2445/185931 |
| Acceso en línea: | https://hdl.handle.net/2445/185931 |
| Access Level: | acceso abierto |
| Palabra clave: | Pneumònia adquirida a la comunitat Mortalitat Corticosteroides Assaigs clínics Septicèmia Community-acquired pneumonia Mortality Adrenocortical hormones Clinical trials Septicemia |
| Sumario: | Background: Community-acquired pneumonia (CAP) is a leading cause of morbidity and mortality worldwide despite correct antibiotic use. Corticosteroids have long been evaluated as a treatment option, but heterogeneous efects on survival have precluded their widespread implementation. We aimed to evaluate whether corticosteroids might improve clinical outcomes in patients with severe CAP and high infammatory responses. Study design and methods: We analyzed two prospective observational cohorts of patients with CAP in Barcelona and Rome who were admitted to intensive care with a high infammatory response. Propensity score (PS) matching was used to obtain balance among the baseline variables in both groups, and we excluded patients with viral pneumonia or who received hydrocortisone. Results: Of the 610 patients admitted with severe CAP, 198 (32%) received corticosteroids and 387 had major criteria for severe CAP. All patients had a baseline serum C-reactive protein above 15 mg/dL. Patients who received corticosteroids were more commonly male, had more comorbidities (e.g., cancer or chronic obstructive pulmonary disease), and presented with signifcantly higher sequential organ failure assessment scores. Eighty-nine patients met major severity criteria (invasive mechanical ventilation and/or septic shock) and were matched per group. Twenty-eightday mortality was lower among patients receiving corticosteroids (16 patients, 18%) than among those not receiving them (28 patients, 31%; p=0.037). After PS matching, corticosteroid therapy reduced the 28-day mortality risk in patients who met major severity criteria (hazard ratio (HR) 0.53, 95% confdence interval (CI) 0.29-0.98) (p=0.043). In patients who did not meet major severity criteria, no benefts were observed with corticosteroid use (HR 0.88 (95%CI 0.32-2.36). Conclusions: Corticosteroid treatment may be of beneft for patients with CAP who have septic shock and/or a high infammatory response and requirement for invasive mechanical ventilation. Corticosteroids appear to have no impact on mortality when these features are not present. |
|---|